8-K filed Nov 12, 2026 at 16:00 ET
Kodiak Sciences reported Q3 2026 results with a net loss of $66.2M ($1.05/share), wider than the $61.5M loss in Q3 2025. The key positive was confirming that both Zenkuda and KSI-501 (tabirafusp-ted) met their primary endpoints in the Phase 3 DAYBREAK study, and the company is on track for a multi-indication BLA submission for Zenkuda by year-end and KSI-101 PEAK data in December 2026. Cash burn remains high, with cash dropping to $88.7M at quarter-end, partially offset by $69M in ATM proceeds raised after the quarter.